Jackie von Salm

Company: Psilera

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Understanding the Mechanism of Non-Hallucinogenic Psilocybin Derivative PSIL-006 11:15 am

Discussing the potential of unique serotonergics in the treatment of neuropsychiatric symptoms associated with neurodegeneration Presenting detailed and mechanistic studies of a non-hallucinogenic psilocybin derivative, PSIL-006 hTau mouse models focused on psychiatric symptomatology including circadian rhythm, socialization, learning, and memoryRead more

day: Day Two Track B - AM

Enhancing the Selectivity, Sensitivity & Predictive Validity of Animal Models to Successfully Translate Novel Antidepressant, Antipsychotic & Anxiolytic Therapeutics 1:00 pm

With a pressing need for in vivo assays that more accurately predict the effects of antidepressants, antipsychotics and anxiolytics in humans, join this collaborative workshop to benchmark new strategies, from recreating exact phenotypes to optimizing dose selection, to bridge the translational gap. Highlights Include: Leveraging advancements in systems neuroscience: which animal behaviours are meaningful indicators…Read more

day: Workshop Day